中医肿瘤学杂志2025，Vol.7Issue(6)：48-55,8.DOI:10.19811/j.cnki.ISSN2096-6628.2025.11.006
回顾性分析双黄升白颗粒对Ⅳ期NSCLC生存期的影响
Effect of Shuanghuang Shengbai Granules on Survival in Patients with Stage Ⅳ NSCLC:A Retrospective Analysis
摘要
Abstract
Objective To evaluate the effect of Shuanghuang Shengbai Granules(SHSB)on progression-free survival(PFS)and overall survival(OS)in patients with stage Ⅳ non-small cell lung cancer(NSCLC).Methods A total of 315 patients with stage Ⅳ NSCLC were enrolled and divided into a high-exposure group(167 patients,continuous administration during and after chemotherapy)and a low-exposure group(148 patients,administration only during chemotherapy).Baseline data,treatment regimens,and survival data were collected.Kaplan-Meier method was used to calculate survival rates,and the Log-rank test was employed to compare differences between two groups.Univariate and multivariate regression analyses were performed using Cox proportional hazards model.Results The median PFS(12.0 months,95%CI:9.09～16.13)and OS(40.5 months,95%CI:37.09～47.90)in the high-exposure group were significantly longer than those in the low-exposure group(PFS:10.0 months,95%CI:6.82～11.77;OS:28.1 months,95%CI:21.28～36.91),with statistically significant differences(P＜0.05).Multivariate analysis showed that high exposure of SHSB was an independent protective factor for OS(HR=0.52,95%CI:0.35～0.74,P=0.004)and PFS(HR=0.36,95%CI:0.24～0.49,P＜0.001).Conclusion SHSB can prolong PFS and OS in patients with stage Ⅳ NSCLC and serve as an independent prognostic protective factor,regardless of chemotherapy,targeted therapy,or immunotherapy.It has significant value as a clinical adjuvant therapy.关键词
双黄升白颗粒/非小细胞肺癌/无进展生存期/总生存期/中医治疗Key words
Shuanghuang Shengbai Granules/non-small cell lung cancer/progression-free survival/overall survival/traditional Chinese medicine therapy分类
医药卫生引用本文复制引用
张俊,王立芳,顾贤,徐振晔..回顾性分析双黄升白颗粒对Ⅳ期NSCLC生存期的影响[J].中医肿瘤学杂志,2025,7(6):48-55,8.基金项目
国家中医药管理局全国名老中医药专家传承工作室建设项目(国中医药人教函[2022]75号). （国中医药人教函[2022]75号）
